{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:28:28Z","timestamp":1792661308349,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.vaccine.2014.04.019","type":"journal-article","created":{"date-parts":[[2014,4,13]],"date-time":"2014-04-13T14:00:17Z","timestamp":1397397617000},"page":"3133-3138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy"],"prefix":"10.1016","volume":"32","author":[{"given":"Bradford D.","family":"Gessner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Feikin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.04.019_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(13)61682-7","article-title":"Using vaccines as probes to define disease burden","author":"Feikin","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0010","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1016\/j.vaccine.2013.05.017","article-title":"Vaccines as a tool to estimate the burden of severe influenza in children of low-resourced areas (November 30\u2013December 1, 2012, Les Pensieres, Veyrier-du-Lac, France)","volume":"31","author":"Gessner","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0015","first-page":"257","article-title":"Use of vaccine trials to estimate burden of disease","volume":"22","author":"Mulholland","year":"2004","journal-title":"J Health Popul Nutr"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0140-6736(04)17664-2","article-title":"Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial","volume":"365","author":"Gessner","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0025","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0140-6736(05)71876-6","article-title":"Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial","volume":"365","author":"Cutts","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0030","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJMoa0904797","article-title":"Effect of human rotavirus vaccine on severe diarrhea in African infants","volume":"362","author":"Madhi","year":"2010","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2014.04.019_bib0035","doi-asserted-by":"crossref","first-page":"A52","DOI":"10.1016\/j.vaccine.2011.08.043","article-title":"Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya","volume":"30","author":"Feikin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0040","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(10)60755-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-congrolled trial","volume":"376","author":"Zaman","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0045","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1056\/NEJMoa0708630","article-title":"Effectiveness of maternal influenza immunization in mothers and infants","volume":"359","author":"Zaman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0050","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/aje\/kwr333","article-title":"On the relations between excess fraction, attributable fraction, and etiologic fraction","volume":"175","author":"Suzuki","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0055","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.2105\/AJPH.89.8.1166","article-title":"Relation of probability of causation to relative risk and doubling dose: a methodologic error that has become a social problem","volume":"89","author":"Greenland","year":"1999","journal-title":"Am J Publ Health"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0060","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1086\/499604","article-title":"A controlled, household-randomized, open-label trial of the effect that treatment of Helicobacter pylori infection has on iron deficiency in children in rural Alaska","volume":"193","author":"Gessner","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0065","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1473-3099(09)70071-4","article-title":"The prevalence of hypoxaemia among ill children in developing countries: a systematic review","volume":"9","author":"Subhi","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0070","series-title":"Vaccines","article-title":"Live attenuated poliovirus vaccines","author":"Sutter","year":"1999"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0075","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children","volume":"365","author":"The RTS,S Clinical Trials Partnership","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0080","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants","volume":"367","author":"The RTS,S Clinical Trials Partnership","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0085","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/S0140-6736(09)61297-6","article-title":"Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial","volume":"374","author":"Sur","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0090","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S1473-3099(13)70273-1","article-title":"5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial","volume":"13","author":"Bhattacharya","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0095","first-page":"893","article-title":"Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease \u2013 United States, 1998\u20132003","volume":"54","author":"Centers for Disease Control and Prevention","year":"2005","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0100","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/ije\/29.4.753","article-title":"Estimation of the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American Indian population","volume":"29","author":"Moulton","year":"2000","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1586\/14760584.8.1.91","article-title":"Haemophilus influenzae type b vaccine impact in resource-poor settings in Asia and Africa","volume":"8","author":"Gessner","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0110","first-page":"20","article-title":"The costs and benefits of a vaccination programme for Haemophilus influenzae type B disease","volume":"85","author":"Hussey","year":"1995","journal-title":"S Afr Med J"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0115","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1097\/00006454-199809001-00003","article-title":"Development, evaluation and implementation of Haemophilus influenzae type b vaccines for young children in developing countries: current status and priority actions","volume":"17","author":"Levine","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2014.04.019_bib0120","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0264-410X(94)00063-S","article-title":"Setting priorities for the Children's Vaccine Initiative: a cost-effectiveness approach","volume":"13","author":"Shepard","year":"1995","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14005210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14005210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:27:23Z","timestamp":1538699243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14005210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":24,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0264410X14005210"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.04.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}